


Product Name : BLU-222
Cat. No. : PC-23995
CAS No. : 2888704-84-3
Molecular Formula : C₁₅H₁₇F₂N₇O₂
Molecular Weight : 365.34
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

Cirtociclib (BLU-222) is a potent, highly selective, ATP-competitive **CDK2** inhibitor with IC₅₀ of 2.6 nM (CDK2/cyclinE1) with strong selectivity (>200-fold) over CDK family members (1/4/6/7/9).

BLU-222 has excellent kinome selectivity with an S(10) of 0.045, measured by KINOMEScan at 3 μM.

BLU-222 displays nanomolar cellular potency on phosphorylated Rb (pRb) T821/826 with strong selectivity over pLamin S22, a measure of CDK1 activity in CDK2-dependent cell line OVCAR-3.

BLU-222 displays nanomolar cellular potency on phosphorylated Rb (pRb) T821/826 with strong selectivity over pLamin S22, a measure of CDK1 activity. BLU-222 potently and dose-dependently inhibited proliferation in CCNE1-amplified ovarian/endometrial cancer cell lines, while sparing CCNE1-normal (diploid, mRNA not overexpressed) cell lines.

BLU-222 disrupts Rb signaling in CCNE1-amplified cells to arrest cell cycle progression. BLU-222 demonstrated robust activity in combination with carboplatin or paclitaxel in CCNE1-aberrant models, rendering chemotherapy-resistant tumors strongly sensitive to the combination.

References

Dommer AP, et al. *Cancer Res.* 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2244.

House NC, et al. *Cancer Res.* 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2360.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com